PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 1466: CellNeighbor: A transcriptional atlas of patient tumors and cell line models to inform preclinical model selection.

View Full Paper
CSCaitlin M. A. SimopoulosRecursion (United States)GPGabrielle PersadUniversity of TorontoOMOtto MorrisRecursion (United States)

Key Points

  • The study aims to improve preclinical model selection by contextualizing cell line models within patient tumor data.
  • Developed the CellNeighbor computational framework to guide model selection based on transcriptomic data.
  • Removed tumor microenvironment-related gene expression variability before integration.
  • Integrated transcriptomic profiles from DepMap and TCGA with patient tumor data using novel metrics.
  • Identified cell lines that are transcriptionally similar to patient tumors, enhancing model selection accuracy.
  • Developed a neighborhood-tissue homogeneity score to quantify model relevance for automated decision making.
  • Increased confidence in cell line selection for specific patient populations.

Abstract

Abstract Preclinical scientists typically select cell line models for compound activity assays based on molecular profiles that support a drug program's hypothesis. However, extensive in vitro culturing of these cell lines can influence genetic changes in these models raising concerns about whether these models still represent the patient tumors from which they were derived. To address this translational gap, we developed CellNeighbor, a computational framework that guides model selection by contextualizing cell lines within the landscape of real-world patient transcriptomic data. Building on the established Celligner framework (1), we explicitly identified and removed tumor microenvironment-related gene expression variability before integrating cell line and patient profiles with Harmony (2). Then, we integrated transcriptomic profiles from DepMap (3,4) with patient tumor data from The Cancer Genome Atlas (TCGA) and deidentified patient tumor data from Tempus, creating a unified transcriptomic map of cell lines and tumors. Within this map, we employ a symmetric nearest neighbor approach to identify "patient neighborhoods" centered around each cell line to characterize cell lines most transcriptionally similar to patient tumors. In addition, we have developed novel metrics, such as a neighborhood-tissue homogeneity score, to quantify the confidence of these associations for use in objective and automated decision making. We can now rank cell lines by their transcriptional similarity to neighborhoods of real patient tumors to increase the likelihood that model lines remain representative of the intended patient population. The integrated clinical and molecular data layers produce a cell line-to-patient map that enables cell line selection tailored to specific patient populations. In conclusion, CellNeighbor offers a robust method to identify cell line models that closely resemble patient tumors, ultimately aiming to increase the translatability of preclinical discoveries into clinical applications. 1.Warren, A., Chen, Y., Jones, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun 12, 22 (2021). https://doi.org/10.1038/s41467-020-20294-x 2.Korsunsky, I., Millard, N., Fan, J. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16, 1289-1296 (2019). https://doi.org/10.1038/s41592-019-0619-0 3.DepMap, Broad (2025). DepMap Public 25Q3. Dataset. depmap.org 4.Arafeh, R., Shibue, T., Dempster, J.M. et al. The present and future of the Cancer Dependency Map. Nat Rev Cancer 25, 59-73 (2025). https://doi.org/10.1038/s41568-024-00763-x Citation Format: Caitlin M. Simopoulos, Gabrielle Persad, Otto Morris, Carlos A. Origel Marmolejo, Laura M. Richards, Kelly M. Biette, . CellNeighbor: A transcriptional atlas of patient tumors and cell line models to inform preclinical model selection abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1466.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Simopoulos et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd4ea79560c99a0a3479https://doi.org/10.1158/1538-7445.am2026-1466
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 7175: Web-based cross-database exploration of molecular pharmacology data from cancer cell lines and patient genomics2024
  2. 2Abstract 1426: A single-cell tumor atlas defines robust pathway and gene signatures enabling cancer cell-line fidelity assessment.2026
  3. 3Abstract B006: An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs2024
  4. 4Abstract 6882: Mechanism-concordant cell-line selection: Bridging real-world tumor drivers and <i>in vitro</i> models for target validation.2026
  5. 5Abstract 3138: CellMiner Cross-Database (CellMinerCDB) for Exploration of Patient-Derived Cancer Cell Line Pharmacogenomics2026